The SURVEYOR study is a trial looking at cognitive changes in people with HD and tested short term safety of dalzanemdor. Read article here written by Dr. Leora Fox, edited…
Dimitri Poffé riding his bike giving visibility to Huntington’s disease – new documentary
An amazing man, Dimitri Poffé, took life by the horns after testing positive for Huntington's disease. He left France to go on an incredible ride across South America. This documentary exemplifies…
Huntington’s Disease Market Report
Read now the most updated, comprehensive report relating to market outlook, drug uptake, treatment scenario and epidemiology trends in Huntington's disease. https://www.einnews.com/pr_news/717150718/huntington-s-disease-market-report-2034-epidemiology-data-pipeline-therapies-latest-approvals-by-delveinsight
Dr. Sarah Tabrizi elected as Fellow of the Royal Society
Dr. Sarah Tabrizi is Director of the UCL Huntington’s Disease Centre and Joint-Head of the Department of Neurodegenerative Disease, at the UCL Queen Square Institute of Neurology. Sarah’s multidisciplinary research…
Unravelling the role of huntingtin: from neurodevelopment to neurodegeneration
The journal, Brain, highlights a recent paper on "Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration". A review by Schultz et al., succinctly summarizes intriguing…
Amazing year for the UCI Sue and Bill Gross Stem Cell Research Center!
HD-CARE supports the UCI Thompson Lab, which is located in the UCI Sue and Bill Gross Stem Cell Research Center (SCRC). The SCRC thanked us for making 2023 an incredible…
Huntington Study Group® and Roche Collaborate on Generation HD2 Study
Exciting new collaboration between the Huntington's Study Group (HSG) and Roche therapeutics. HSG will advise Roche on recruitment and enrollment of the needs of GENERATION HD2. This work will collectively…
SAGE Therapeutics announces FDA approved drug for HD cognitive therapy
SAGE therapeutics is a biopharmaceutical company with the mission of improving brain health. On 11/13/23, SAGE announcted that the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD)…
New FDA Approved Drug for Chorea
The Huntington Study Group (HSG) shared that the Phase 3 KINECT-HD study resulted in FDA approval of valbenazine for treatment of chorea in Huntington's disease (HD). As a vesicular monoamine…
What is Huntington’s Disease? Find out in this Podcast!
Dr. Leslie Thompson, professor of Psychiatry & Human Behavior, Neurobiology and Behavior, and Chemistry, discusses Huntington's Disease and possible treatment strategies on the UCI MIND podcast. Check out the full…